Safety - Pharmaceutical Executive

ADVERTISEMENT

Safety

Life After FDA

October 1, 2007

You have to admit: Mark McClellan, MD, has quite a resumé. But after you've been the commissioner of FDA and the administrator of the Centers for Medicare and Medicaid Services (CMS), what comes next?

Drug Safety: Failure to Communicate

September 1, 2007

Many see Vioxx and Avandia as clear signs that the drug safety system has failed. As soon as reports of these drugs' adverse events began to flood the media, consumers—and Congress—demanded to know: "Why didn't we know sooner?"

Zelnorm Returns--Sort Of

August 1, 2007

Novartis' Zelnorm is back, but only through a restricted-access program.

Avandia Sales Away

July 30, 2007

Avandia's market share erosion was magnified further by the almost complete absence of new prescriptions being switched to Avandia from its competitors. In the weeks before the event, Avandia accounted for more than 20 percent of all switches by primary care physicians

Safety Net

July 30, 2007

A new class of scales that can help capture drug effects—not necessarily disease impacts, as quality-of-life instruments currently do—will likely be needed to identify the meaning of the drug's benefits to patients

The Oprah Moment

July 18, 2007

In the wake of a high-profile death from counterfeit drugs, the industry reacts

In Sync with California

July 3, 2007

Although pricey, serialization with RFID is expected to reduce logistical errors and address some aspects of supply chain security

Culture Shock

July 3, 2007

What's old and established is in, what's new—and once interpreted as"better"—is out

ADVERTISEMENT

Click here